How to Prescribe

Qsymia® is now available at Qsymia-certified retail pharmacies.
It can also be mail ordered from certified pharmacies in the Qsymia Home Delivery Network.

Write 2 prescriptions:

  • 14 days on Qsymia® starting
    dose of 3.75 mg/23 mg
  • 30 days on recommended dose
    of 7.5 mg/46 mg
  • No generic equivalent
    -Dispense as written
  • Include: DEA#, dose strength,
    and patient information.

Instruct your patients to visit www.findQsymia.com to locate a Qsymia-certified retail pharmacy

Or fax or mail prescription for mail-order delivery

Prior Authorization Assistance

Qsymia® makes it easier by helping you navigate the prior authorization process. VIVUS and PARx Solutions, Inc. have partnered to support providers and office staff with the Prior Authorization Support System (PASS).

PASS Provider Registration instructions

  • Go to www.parxsolutions.com/Provider
  • Click on “Register” and follow the instructions
  • Review program requirements and sign the Business Associate Agreement
  • Log in and review the instructional tutorial on the “Status Page”

How patients will obtain the medication

  • Qsymia® is now available at Qsymia-certified retail pharmacies.
    Prescriptions can also be filled through mail order by the select pharmacies in the Qsymia Home Delivery Network
  • Patients will receive Qsymia every 30 days
  • Patients may receive up to 5 refills at the prescriber’s discretion. Patients should call the pharmacy 10 business days before each refill is needed

Next: Resources

INDICATION

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m2 or greater (obese) or
  • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia

Limitations of Use:

  • The effect of Qsymia on cardiovascular morbidity and mortality has not been established
  • The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established

Important Safety Information

Qsymia® is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

Qsymia can cause an increase in resting heart rate. Regular measurement of resting heart rate is recommended for all patients taking Qsymia, especially patients with cardiac or cerebrovascular disease or when initiating or increasing the dose of Qsymia. Qsymia has not been studied in patients with recent or unstable cardiac or cerebrovascular disease and therefore use is not recommended.

Topiramate, a component of Qsymia, increases the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Qsymia in patients who experience suicidal thoughts or behaviors. Qsymia is not recommended in patients with a history of suicidal attempts or active suicidal ideation.

Acute angle closure glaucoma has been reported in patients treated with topiramate, a component of Qsymia. Symptoms include acute onset of decreased visual acuity and/or eye pain. Symptoms typically occur within 1 month of initiating treatment with topiramate but may occur at any time during therapy. The primary treatment to reverse symptoms is immediate discontinuation of Qsymia.

Qsymia can cause mood disorders, including depression, and anxiety, as well as insomnia. Qsymia can cause cognitive dysfunction (e.g., impairment of concentration/attention, difficulty with memory, and speech or language problems, particularly word-finding difficulties). Since Qsymia has the potential to impair cognitive function, patients should be cautioned about operating hazardous machinery, including automobiles.

Hyperchloremic, non-anion gap, metabolic acidosis has been reported in patients treated with Qsymia. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing Qsymia.

Qsymia can cause an increase in serum creatinine. If persistent elevations in creatinine occur while taking Qsymia, reduce the dose or discontinue Qsymia.

Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus treated with insulin and/or insulin secretagogues (e.g., sulfonylureas). Qsymia has not been studied in combination with insulin. A reduction in the dose of antidiabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia.

The most commonly observed side effects in controlled clinical studies, ≥5% and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

To report negative side effects, contact VIVUS, Inc. at 1-888-998-4887 or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.

References:

  1. Qsymia® (phentermine and topiramate extended-release) capsules CIV [Prescribing Information]. Mountain View, CA: VIVUS, Inc.; 2013.


Share With a Friend

*Indicates required field.

(email address)
(email address)

 

Qsymia® (phentermine and topiramate extended-release) capsules CIV is an FDA-approved therapy for the treatment of obesity.

For Healthcare Professionals

Find out how Qsymia may help your obese patients who are struggling with their weight.

Learn More

For Pharmacists

Learn about filling Qsymia prescriptions through Qsymia-certified pharmacies.

Learn More

Qsymia® (phentermine and topiramate extended-release) capsules CIV is an FDA-approved therapy for the treatment of obesity.

For Healthcare Professionals

Find out how Qsymia may help your obese patients achieve significant weight loss for 1 year.

Learn More

For Pharmacists

Learn about how prescriptions are filled through Qsymia-certified pharmacies.

Learn More

Your BMI is: